摘要
目的评价硼替佐米对治疗继发性浆细胞白血病患者血清M蛋白及临床疗效影响研究。方法 20例继发性浆细胞白血病患者随机分为对照组及试验组;对照组9例,给予醋酸泼尼松龙片,60 mg/（m2·d）,口服,d1~d4＋马法兰片,8 mg/（m^2·d）,口服,d1~d4＋沙利度胺,100~200 mg/d,口服,睡前;试验组11例,在对照组基础上加用注射用硼替佐米,1.3 mg/（m^2·d）,静脉推注,d1、d4、d8、d11。比较2组患者治疗前后骨髓浆细胞比例、血清M蛋白（IgA、IgG）水平、治疗有效率及安全性。结果治疗后,与对照组比较,试验组患者浆细胞比例、M蛋白水平较低（P〈0.05）。试验组的治疗有效率（54.55%）显著高于对照组（11.11%）（P〈0.05）,其结果均有统计学意义。结论硼替佐米能够显著降低继发性浆细胞白血病患者的骨髓浆细胞比例及血清M蛋白水平,提高临床疗效,且安全性较高。
Objective To evaluate the effect of Bortezomib in the treatment of secondary plasma cell leukemia in serum M protein and clinical efficacy.Methods20 cases of patients with secondary plasma cell leukemia were randomly divided into the control group and treatment group, 9 cases in the control group,11 cases in the treatment group.The control group was given Prednisolone acetate tablets 60mg/（m2·d）,oral, d1~d4 ＋ Melphalan tablets, 8mg/（m2·d）,oral, d1~d4＋Thalidomide 100~200mg/d, oral, bedtime;on the basis of the control group, the experimental group was treated with Bortezomib for Injection, 1.3mg/（m2·d）, intravenous injection, d1、d4、d8、d11.Before and after treatment, compared between the two groups of patients with the ratio of bone marrow plasma cells, serum monoclonicity Immunoglobulin A （IgA）, monoclonicity immunoglobulin G （IgG） levels, efficiency of treatment and safety.ResultsAfter treatment, compared with the control group,the plasma cell ratio, the serum levels of IgA and IgG were lower in the experimental group （P〈0.05）;the treatment efficiency of the experimental group （54.55%） was significantly higher than that of the control group （11.11%）, the results were statistically significant.ConclusionThe Bortezomib can significantly reduce the ratio of bone marrow plasma cells and the serum levels of monoclonicity IgA、IgG in patients with secondary plasma cell leukemia, improve clinical efficacy, and the safety was high.
出处
《中国生化药物杂志》
CAS
2017年第5期311-312,315,共3页
Chinese Journal of Biochemical Pharmaceutics
